biote Corp. (NASDAQ:BTMD) Major Shareholder Acquires $22,615.46 in Stock

biote Corp. (NASDAQ:BTMD) major shareholder Guines Llc purchased 6,874 shares of the business’s stock in a transaction on Thursday, April 17th. The shares were acquired at an average price of $3.29 per share, with a total value of $22,615.46. Following the completion of the transaction, the insider now owns 4,164,300 shares of the company’s stock, valued at approximately $13,700,547. This trade represents a 0.17 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Guines Llc also recently made the following trade(s):

• On Wednesday, April 9th, Guines Llc bought 13,532 shares of biote stock. The stock was bought at an average cost of $3.21 per share, with a total value of $43,437.72.
• On Monday, April 7th, Guines Llc purchased 43,378 shares of biote stock. The shares were bought at an average price of $3.15 per share, for a total transaction of $136,640.70.
• On Thursday, April 3rd, Guines Llc acquired 7,321 shares of biote stock. The shares were bought at an average cost of $3.24 per share, with a total value of $23,720.04.
• On Monday, March 31st, Guines Llc bought 106,000 shares of biote stock. The stock was purchased at an average cost of $3.32 per share, for a total transaction of $351,920.00.
• On Monday, March 17th, Guines Llc purchased 100 shares of biote stock. The shares were purchased at an average cost of $3.74 per share, with a total value of $374.00.
• On Thursday, March 13th, Guines Llc acquired 750,000 shares of biote stock. The stock was purchased at an average price of $3.22 per share, for a total transaction of $2,415,000.00.

biote Stock Performance

BTMD opened at $3.30 on Monday. The stock has a market capitalization of $180.54 million, a PE ratio of 12.69 and a beta of 1.17. The stock’s 50 day moving average price is $3.92 and its 200-day moving average price is $5.12. biote Corp. has a 52-week low of $3.04 and a 52-week high of $8.44.

Wall Street Analyst Weigh In

Separately, Craig Hallum cut their target price on biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in BTMD. Dimensional Fund Advisors LP raised its stake in biote by 0.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 681,524 shares of the company’s stock worth $4,211,000 after buying an additional 3,065 shares in the last quarter. Jane Street Group LLC raised its position in shares of biote by 24.7% in the 3rd quarter. Jane Street Group LLC now owns 16,873 shares of the company’s stock worth $94,000 after acquiring an additional 3,342 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in shares of biote by 10.2% in the 4th quarter. Ameriprise Financial Inc. now owns 36,214 shares of the company’s stock valued at $224,000 after purchasing an additional 3,351 shares during the period. Rhumbline Advisers lifted its stake in shares of biote by 11.6% in the 4th quarter. Rhumbline Advisers now owns 37,688 shares of the company’s stock valued at $233,000 after purchasing an additional 3,920 shares during the period. Finally, Wells Fargo & Company MN boosted its position in shares of biote by 49.9% during the fourth quarter. Wells Fargo & Company MN now owns 12,742 shares of the company’s stock valued at $79,000 after purchasing an additional 4,243 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.